NCT02504619View on ClinicalTrials.gov

Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 4, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

December 31, 2017

Conditions
Sickle Cell DiseaseThalassemia
Interventions
BIOLOGICAL

CordIn

CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.

Trial Locations (3)

20010

Children's National, Washington D.C.

94609

UCSF Benioff Children's Hospital, Oakland

Unknown

Hôpital Robert Debré, Paris

Sponsors

Lead Sponsor

Gamida Cell ltd
All Listed Sponsors
lead

Gamida Cell ltd

INDUSTRY